kleanprep - search results

Germany - English - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

eziclen konzentrat zur herstellung einer lösung zum einnehmen

United States - English - NLM (National Library of Medicine)

blenrep- belantamab injection, powder, lyophilized, for solution

glaxosmithkline llc - belantamab mafodotin (unii: db1041cxdg) (belantamab mafodotin - unii:db1041cxdg) - blenrep is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-cd38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. this indication is approved under accelerated approval based on response rate [see clinical studies (14)] . continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). none. risk summary based on its mechanism of action, blenrep can cause fetal harm when administered to a pregnant woman, because it contains a genotoxic compound (the microtubule inhibitor, mmaf) and it targets actively dividing cells [see clinical pharmacology (12.1), nonclinical toxicology (13.1)] . human immunoglobulin g (igg) is known to cross the placenta; therefore, belantamab mafodotin-blmf has the potential to be transmitted from the mother to the developing fetus. there are no available data on the use of blenrep in pregnan

European Union - English - EMA (European Medicines Agency)

blenrep

glaxosmithkline (ireland) limited - belantamab mafodotin - multiple myeloma - antineoplastic agents - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Israel - English - Ministry of Health

blenrep

glaxo smith kline (israel) ltd - belantamab mafodotin - powder for concentrate for solution for infusion - belantamab mafodotin 100 mg - belantamab - blenrep is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-cd38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.

United States - English - NLM (National Library of Medicine)

clearprep fx- salicylic acid gel

cover fx skin care, inc. - salicylic acid (unii: o414pz4lpz) (salicylic acid - unii:o414pz4lpz) - salicylic acid 1 g in 100 ml - matte foundation primer and anti-acne treatment gel use: helps treat acne pimples and allows skin to heal.